May rarely cause hypersensitivity, anaphylaxis, anaphylactoid reactions, angioedema, bronchospasm, and erythema. Hypertriglyceridemia is expected side effect. Patients who develop hypertriglyceridemia (e.g. >500 mg/dL) are at risk of developing pancreatitis (use with caution in pre-existing hyperlipidemia). Major cardiovascular effect hypotension especially if patient is hypovolemic or if bolus dosing is used (use with caution in patients who are hemodynamically unstable, hypovolemic, or have abnormally low vascular tone (e.g. sepsis)). Transient local pain may occur during I.V. injection. Perioperative myoclonus (e.g. convulsions and opisthotonos) occurred with administration. Propofol-related infusion syndrome is serious side-effect with high mortality rate characterized by dysrhythmia (e.g. bradycardia or tachycardia), heart failure, hyperkalemia, lipemia, metabolic acidosis, and/or rhabdomyolysis or myoglobinuria with subsequent renal failure. Use with caution in severe cardiac disease (ejection fraction <50%) or hypotension (may have more profound adverse cardiovascular responses to propofol). Use with caution in increased intracranial pressure or impaired cerebral circulation (substantial decreases in mean arterial pressure and subsequent decreases in cerebral perfusion pressure may occur). Propofol vials and prefilled syringes have potential risk of infection. Use with caution in pre-existing pancreatitis (may be exacerbated), in respiratory disease, and in history of epilepsy or seizures (seizure may occur during recovery phase). Concomitant use with opiates may lead to increased sedative or anesthetic effects of propofol, more pronounced decreases in systolic, diastolic, and mean arterial pressures and cardiac output. In addition, fentanyl may cause serious bradycardia when used with propofol in pediatric patients. Alfentanil use with propofol precipitated seizure activity in patients without history of epilepsy. Caution in elderly and debilitated patients (risk of cardiorespiratory-depressive events). Concurrent use of fentanyl and propofol in pediatric patients may result in bradycardia. Propofol should only be used in pregnancy if clearly needed. Not recommended for use in obstetrics, including cesarean section deliveries. Some products may contain benzyl alcohol («gasping syndrome» in neonates). Some formulations contain edetate disodium; may lead to decreased zinc levels in prolonged therapy (>5 days) or predisposition to zinc deficiency (e.g. burns, diarrhea, or sepsis). Some formulations may contain sulfites. Abrupt discontinuation should be avoided (can result in rapid awakening, anxiety, agitation, and resistance to mechanical ventilation).